Dr. Reddy's Laboratories Ltd. Sponsored ADR
(NYSE : RDY)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Generic
symbolcompany%chnglast%shortavg$volume
AGNAllergan plc
0.09%136.722.8%$458.34m
ZTSZoetis, Inc. Class A
1.22%94.611.9%$222.37m
TEVATeva Pharmaceutical Industries Limited Sponsored ADR
0.06%17.262.1%$134.53m
MYLMylan N.V.
0.64%31.263.2%$131.02m
TXMDTherapeuticsMD, Inc.
6.09%5.4025.3%$18.17m
RDYDr. Reddy's Laboratories Ltd. Sponsored ADR
2.38%36.862.0%$9.75m
TAROTaro Pharmaceutical Industries Ltd.
-0.93%101.736.4%$7.11m
LFVNLifeVantage Corporation
-0.91%15.313.3%$2.70m
ABEOAbeona Therapeutics, Inc.
1.41%6.477.8%$2.51m
KINKindred Biosciences, Inc.
0.09%10.630.3%$1.96m
PETXAratana Therapeutics, Inc.
-1.16%4.278.5%$1.63m
JAGXJaguar Animal Health, Inc.
-1.75%0.239.8%$0.07m
CPHIChina Pharma Holdings, Inc.
6.20%0.280.1%$0.05m

Company Profile

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others. The Global Generics segment is consist of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The PSAI segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.